Return to study ST001391 main page
MB Sample ID: SA113258
| Local Sample ID: | PTLDS_JHU_19OYFU |
| Subject ID: | SU001465 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU001465 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
Factors:
| Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
|---|---|---|---|---|
| PTLDS_JHU_19OYFU | SA113258 | FL014257 | One-year follow-up | Time point |
| PTLDS_JHU_19OYFU | SA113258 | FL014257 | No | PTLDS |
Collection:
| Collection ID: | CO001460 |
| Collection Summary: | Sera (both cohorts) were collected at the time of diagnosis (baseline); at the completion of antibiotic therapy, approximately two to three weeks following diagnosis (post-treatment); and at one-year post-treatment (one-year follow-up). PTLDS (symptoms) patients were classified as such if symptoms developed at or within 6 months following diagnosis and persisted for at least 6 months following the completion of antibiotic therapy. Patients were classified as PTLDS (syndrome) if they met the above criteria and with daily life functional impairment reported. |
| Sample Type: | Blood (serum) |
Treatment:
| Treatment ID: | TR001480 |
| Treatment Summary: | N/A |
Sample Preparation:
| Sampleprep ID: | SP001473 |
| Sampleprep Summary: | Serum samples were randomized prior to extraction of small molecule metabolites and LC-MS analyses. Metabolites were extracted with 75% methanol as previously described. Extracted metabolites were analyzed by LC-MS. |
| Sampleprep Protocol Comments: | doi:10.1038/nprot.2011.335 |
Combined analysis:
| Analysis ID | AN002320 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Agilent 6520 |
| Column | Poroshell 120 EC-C8 (100 x 2.1mm,2.5um) |
| MS Type | ESI |
| MS instrument type | QTOF |
| MS instrument name | Agilent 6520 QTOF |
| Ion Mode | POSITIVE |
| Units | counts |
Chromatography:
| Chromatography ID: | CH001705 |
| Instrument Name: | Agilent 6520 |
| Column Name: | Poroshell 120 EC-C8 (100 x 2.1mm,2.5um) |
| Column Temperature: | 50 |
| Flow Gradient: | 2-98% non-linear gradient |
| Flow Rate: | 0.25 ml/min |
| Solvent A: | 100% water; 0.1% formic acid |
| Solvent B: | 100% acetonitrile; 0.1% formic acid |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS002162 |
| Analysis ID: | AN002320 |
| Instrument Name: | Agilent 6520 QTOF |
| Instrument Type: | QTOF |
| MS Type: | ESI |
| MS Comments: | LC-MS data were processed with MassHunter Profinder version B.08.00 and Mass Profiler Professional version B.14.9.01 (Agilent Technologies) to identify differentiating molecular features (MFs; metabolites defined by a retention time and accurate mass) between PTLDS and non-PTLDS patients at baseline, post-treatment and one-year follow-up in cohort-one. The biosignature-MFs determined using cohort-one were targeted in patient samples from cohort-two using MassHunter Profinder. |
| Ion Mode: | POSITIVE |
| Capillary Voltage: | 4000 |
| Dry Gas Flow: | 10 l/min |
| Dry Gas Temp: | 310 |
| Fragment Voltage: | 120 |
| Nebulizer: | 45 psi |
| Octpole Voltage: | 750 V |
